However, the 2022 World Health Organization (WHO) and International Consensus Classification (ICC) recommendations re-categorized MYC/BCL6 as “DLBCL, not otherwise specified” and MYC/BCL2 and MYC/BLC2/BCL6 as “DLBCL/high-grade B-cell lymphoma-MYC/BCL2” [34, 40, 41]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.